Holen Sie sich die Stockscreener-App
20.74
0.00%
0.00
Handel nachbörslich:
20.75
0.01
+0.05%
Schlusskurs vom Vortag:
$20.74
Offen:
$20.7
24-Stunden-Volumen:
235.84K
Relative Volume:
0.79
Marktkapitalisierung:
$667.00M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-3.7417
EPS:
-5.5429
Netto-Cashflow:
$-51.44M
1W Leistung:
+8.93%
1M Leistung:
+23.05%
6M Leistung:
-8.47%
1J Leistung:
-25.82%
1-Tages-Spanne:
$20.10
$21.05
1-Wochen-Bereich:
$19.13
$21.59
52-Wochen-Spanne:
$13.37
$32.27
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Firmenname
Dianthus Therapeutics Inc
Sektor
Branche
Telefon
929-999-4055
Adresse
7 TIMES SQUARE, NEW YORK
Vergleichen Sie DNTH mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
20.74 | 612.33M | 4.12M | -56.68M | -51.44M | -5.5429 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-02 | Eingeleitet | William Blair | Outperform |
| 2024-12-20 | Eingeleitet | TD Cowen | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-15 | Eingeleitet | Stifel | Buy |
| 2023-12-26 | Eingeleitet | Jefferies | Buy |
| 2023-11-22 | Eingeleitet | Wedbush | Outperform |
| 2023-10-30 | Eingeleitet | Guggenheim | Buy |
| 2023-09-28 | Eingeleitet | Raymond James | Outperform |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-06 | Hochstufung | Goldman | Neutral → Buy |
| 2021-08-20 | Fortgesetzt | Goldman | Neutral |
| 2021-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Bestätigt | B. Riley Securities | Buy |
| 2021-06-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-18 | Eingeleitet | B. Riley Securities | Buy |
| 2021-01-07 | Eingeleitet | Mizuho | Buy |
| 2020-06-08 | Hochstufung | Goldman | Neutral → Buy |
| 2019-03-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics Inc. Stock Analysis and ForecastSuperior portfolio returns - jammulinksnews.com
Is Dianthus Therapeutics Inc. a good long term investmentRapid wealth creation - jammulinksnews.com
What analysts say about Dianthus Therapeutics Inc. stockOutstanding capital returns - Autocar Professional
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5.9%Should You Buy? - MarketBeat
Brokerages Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Target Price at $53.00 - MarketBeat
What drives Dianthus Therapeutics Inc. stock priceUnmatched profit growth - jammulinksnews.com
why dianthus therapeutics inc. stock attracts strong analyst attentionSafe and Smart Investment Picks - Newser
what makes dianthus therapeutics inc. stock price move sharplyVolume Spike Monitors - Newser
What makes Dianthus Therapeutics Inc. stock price move sharplyFree Deep Market Trend Analysis - Newser
How Dianthus Therapeutics Inc. stock performs during market volatilityFree Stock Selection - Newser
Why Dianthus Therapeutics Inc. stock attracts strong analyst attentionTriple Return With Stability - Newser
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.9%Should You Sell? - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 8.4%Should You Buy? - MarketBeat
DNTH’s Stock Market Adventure: -16.38% YTD Growth Amidst Volatility - investchronicle.com
What is William Blair's Estimate for DNTH FY2025 Earnings? - MarketBeat
William Blair Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat
FY2025 Earnings Estimate for DNTH Issued By William Blair - Defense World
Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated at William Blair - Defense World
Dianthus Therapeutics stock rises after William Blair initiates coverage By Investing.com - Investing.com Canada
Dianthus Therapeutics Shares Climb After Analyst Coverage Boost - MSN
William Blair Initiates Dianthus Therapeutics at Outperform - MarketScreener
Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6%Time to Sell? - MarketBeat
Is Dianthus Therapeutics, Inc. overvalued or undervalued? - MarketsMojo
What is Lifesci Capital’s Estimate for DNTH Q2 Earnings? - Defense World
Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside - MSN
Buy Rating for Dianthus Therapeutics: Promising Growth Potential of DNTH103 in Neuromuscular Disease Treatment - TipRanks
Equities Analysts Issue Forecasts for DNTH FY2026 Earnings - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%What's Next? - MarketBeat
Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):